Table 1 (abstract P317). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | 2 doses (n=65) | 3 doses (n=46) |
|---|---|---|
Gender (F, %) | 95% | 93% |
Age at onset [median (IQR)] | 15 (12-16) | 15 (12-16) |
Disease duration at first dose [months, median (IQR)] | 192 (109-332) | 229 (143-345) |
Age at first dose [years, (IQR)] | 32 (25-41) | 33 (26-45) |
Ongoing immunosuppressors, n | 25 | 18 |
Ongoing belimumab, n | 9 | 9 |